

SUPPLEMENTARY REFERENCES

1. Anderson JJ, Couper JJ, Giles LC, Leggett CE, Gent R, Coppin B, et al. Effect of metformin on vascular function in children with type 1 diabetes: a 12-month randomized controlled trial. *J Clin Endocrinol Metab* 2017;102:4448-56.
2. Codner E, Iniguez G, Lopez P, Mujica V, Eyzaguirre FC, Asenjo S, et al. Metformin for the treatment of hyperandrogenism in adolescents with type 1 diabetes mellitus. *Horm Res Paediatr* 2013;80:343-9.
3. Hamilton J, Cummings E, Zdravkovic V, Finegood D, Dane-man D. Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial. *Diabetes Care* 2003;26:138-43.
4. Jacobsen IB, Henriksen JE, Beck-Nielsen H. The effect of metformin in overweight patients with type 1 diabetes and poor metabolic control. *Basic Clin Pharmacol Toxicol* 2009;105:145-9.
5. Lund SS, Tarnow L, Astrup AS, Hovind P, Jacobsen PK, Alibegovic AC, et al. Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control: a randomized study. *PLoS One* 2008;3:e3363.
6. Lund SS, Tarnow L, Astrup AS, Hovind P, Jacobsen PK, Alibegovic AC, et al. Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes. *Diabetes Obes Metab* 2009;11:966-77.
7. Libman IM, Miller KM, DiMeglio LA, Bethin KE, Katz ML, Shah A, et al. Effect of metformin added to insulin on glycemic control among overweight/obese adolescents with type 1 diabetes: a randomized clinical trial. *JAMA* 2015;314:2241-50.
8. Meyer L, Bohme P, Delbachian I, Lehert P, Cugnardey N, Drouin P, et al. The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients. *Diabetes Care* 2002;25:2153-8.
9. Nadeau KJ, Chow K, Alam S, Lindquist K, Campbell S, McFann K, et al. Effects of low dose metformin in adolescents with type I diabetes mellitus: a randomized, double-blinded placebo-controlled study. *Pediatr Diabetes* 2015;16:196-203.
10. Nwosu BU, Maranda L, Cullen K, Greenman L, Fleshman J, McShea N, et al. A randomized, double-blind, placebo-controlled trial of adjunctive metformin therapy in overweight/obese youth with type 1 diabetes. *PLoS One* 2015;10:e0137525.
11. Petrie JR, Chaturvedi N, Ford I, Hramiak I, Hughes AD, Jenkins AJ, et al. Metformin in adults with type 1 diabetes: design and methods of Reducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): an international multicentre trial. *Diabetes Obes Metab* 2017;19:509-16.
12. Petrie JR, Chaturvedi N, Ford I, Brouwers MC, Greenlaw N, Tillin T, et al. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. *Lancet Diabetes Endocrinol* 2017;5:597-609.
13. Pitocco D, Zaccardi F, Tarzia P, Milo M, Scavone G, Rizzo P, et al. Metformin improves endothelial function in type 1 diabetic subjects: a pilot, placebo-controlled randomized study. *Diabetes Obes Metab* 2013;15:427-31.
14. Sarnblad S, Kroon M, Aman J. Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomised placebo-controlled trial with aspects on insulin sensitivity. *Eur J Endocrinol* 2003;149:323-9.
15. Ziaee A, Esmailzadehha N, Honardoost M. Comparison of adjunctive therapy with metformin and acarbose in patients with type-1 diabetes mellitus. *Pak J Med Sci* 2017;33:686-90.
16. Khan AS, McLoughney CR, Ahmed AB. The effect of metformin on blood glucose control in overweight patients with type 1 diabetes. *Diabet Med* 2006;23:1079-84.
17. Hollander P, Pi-Sunyer X, Coniff RF. Acarbose in the treatment of type I diabetes. *Diabetes Care* 1997;20:248-53.
18. Riccardi G, Giacco R, Parillo M, Turco S, Rivellese AA, Ventura MR, et al. Efficacy and safety of acarbose in the treatment of type 1 diabetes mellitus: a placebo-controlled, double-blind, multicentre study. *Diabet Med* 1999;16:228-32.
19. Dimitriadis G, Hatzigelaki E, Ladas S, Linos A, Hillebrand I, Raptis S. Effects of prolonged administration of two new alpha-glucosidase inhibitors on blood glucose control, insulin requirements and breath hydrogen excretion in patients with insulin-dependent diabetes mellitus. *Eur J Clin Invest* 1988;18:33-8.
20. Marena S, Tagliaferro V, Cavallero G, Pagani A, Montegrosso G, Bianchi W, et al. Double-blind crossover study of acarbose in type 1 diabetic patients. *Diabet Med* 1991;8:674-8.
21. McCulloch DK, Kurtz AB, Tattersall RB. A new approach to the treatment of nocturnal hypoglycemia using alpha-glucosidase inhibition. *Diabetes Care* 1983;6:483-7.
22. Serrano-Rios M, Saban J, Navascues I, Canizo JF, Hillebrand I. Effect of two new alpha-glucosidase inhibitors in insulin-dependent diabetic patients. *Diabetes Res Clin Pract* 1988;4:111-6.
23. Kennedy FP, Gerich JE. A new alpha-glucosidase inhibitor (Bay-m-1099) reduces insulin requirements with meals in in-

- sulin-dependent diabetes mellitus. *Clin Pharmacol Ther* 1987; 42:455-8.
24. Kennedy FP, Gerich JE. Alpha-glucosidase inhibition and timing of preprandial insulin in patients with insulin-dependent diabetes mellitus (IDDM). *Diabetes Res Clin Pract* 1988;4:309-12.
 25. Bhat R, Bhansali A, Bhadada S, Sialy R. Effect of pioglitazone therapy in lean type 1 diabetes mellitus. *Diabetes Res Clin Pract* 2007;78:349-54.
 26. Strowig SM, Raskin P. The effect of rosiglitazone on overweight subjects with type 1 diabetes. *Diabetes Care* 2005;28:1562-7.
 27. Tafuri KS, Godil MA, Lane AH, Wilson TA. Effect of pioglitazone on the course of new-onset type 1 diabetes mellitus. *J Clin Res Pediatr Endocrinol* 2013;5:236-9.
 28. Zdravkovic V, Hamilton JK, Daneman D, Cummings EA. Pioglitazone as adjunctive therapy in adolescents with type 1 diabetes. *J Pediatr* 2006;149:845-9.
 29. Stone ML, Walker JL, Chisholm D, Craig ME, Donaghue KC, Crock P, et al. The addition of rosiglitazone to insulin in adolescents with type 1 diabetes and poor glycaemic control: a randomized-controlled trial. *Pediatr Diabetes* 2008;9(4 Pt 1):326-34.
 30. Ahren B, Hirsch IB, Pieber TR, Mathieu C, Gomez-Peralta F, Hansen TK, et al. Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the ADJUNCT TWO randomized trial. *Diabetes Care* 2016;39:1693-701.
 31. Dejgaard TF, Frandsen CS, Hansen TS, Almdal T, Urhammer S, Pedersen-Bjergaard U, et al. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. *Lancet Diabetes Endocrinol* 2016;4:221-32.
 32. Dejgaard TF, Johansen NB, Frandsen CS, Asmar A, Tarnow L, Knop FK, et al. Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes. *Diabetes Obes Metab* 2017;19:734-8.
 33. Frandsen CS, Dejgaard TF, Holst JJ, Andersen HU, Thorsteinsson B, Madsbad S. Twelve-week treatment with liraglutide as add-on to insulin in normal-weight patients with poorly controlled type 1 diabetes: a randomized, placebo-controlled, double-blind parallel study. *Diabetes Care* 2015;38:2250-7.
 34. Frandsen CS, Dejgaard TF, Andersen HU, Holst JJ, Hartmann B, Thorsteinsson B, et al. Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: a randomized, placebo-controlled, double-blind, parallel-group study. *Diabetes Obes Metab* 2017;19:773-82.
 35. Kuhadiya ND, Dhindsa S, Ghanim H, Mehta A, Makdissi A, Batra M, et al. Addition of liraglutide to insulin in patients with type 1 diabetes: a randomized placebo-controlled clinical trial of 12 weeks. *Diabetes Care* 2016;39:1027-35.
 36. Mathieu C, Zinman B, Hemmingsson JU, Woo V, Colman P, Christiansen E, et al. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treatment-target randomized trial. *Diabetes Care* 2016;39:1702-10.
 37. Dube MC, D'Amours M, Weisnagel SJ. Beyond glycaemic control: a cross-over, double-blinded, 24-week intervention with liraglutide in type 1 diabetes. *Diabetes Obes Metab* 2018;20:178-84.
 38. Garg SK, Moser EG, Bode BW, Klaff LJ, Hiatt WR, Beatson C, et al. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. *Endocr Pract* 2013;19:19-28.
 39. Ellis SL, Moser EG, Snell-Bergeon JK, Rodionova AS, Hazenfield RM, Garg SK. Effect of sitagliptin on glucose control in adult patients with type 1 diabetes: a pilot, double-blind, randomized, crossover trial. *Diabet Med* 2011;28:1176-81.
 40. Farngren J, Persson M, Schweizer A, Foley JE, Ahren B. Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes. *J Clin Endocrinol Metab* 2012;97:3799-806.
 41. Foley JE, Ligueros-Saylan M, He YL, Holst JJ, Deacon CF, Dunning BE, et al. Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes. *Horm Metab Res* 2008;40:727-30.
 42. George PS, McCrimmon RJ. Saxagliptin co-therapy in C-peptide negative type 1 diabetes does not improve counter-regulatory responses to hypoglycaemia. *Diabet Med* 2016;33:1283-90.
 43. Schopman JE, Hoekstra JB, Frier BM, Ackermans MT, de Sonnaville JJ, Stades AM, et al. Effects of sitagliptin on counter-regulatory and incretin hormones during acute hypoglycaemia in patients with type 1 diabetes: a randomized double-blind placebo-controlled crossover study. *Diabetes Obes Metab* 2015;17:546-53.
 44. Buse JB, Garg SK, Rosenstock J, Bailey TS, Banks P, Bode BW, et al. Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTan-

- dem1 Study. *Diabetes Care* 2018;41:1970-80.
45. Dandona P, Mathieu C, Phillip M, Hansen L, Griffen SC, Tschöpe D, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. *Lancet Diabetes Endocrinol* 2017;5: 864-76.
 46. Danne T, Cariou B, Banks P, Brandle M, Brath H, Franek E, et al. HbA1c and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 Study. *Diabetes Care* 2018;41:1981-90.
 47. Famulla S, Pieber TR, Eilbracht J, Neubacher D, Soleymanlou N, Woerle HJ, et al. Glucose exposure and variability with empagliflozin as adjunct to insulin in patients with type 1 diabetes: continuous glucose monitoring data from a 4-week, randomized, placebo-controlled trial (EASE-1). *Diabetes Technol Ther* 2017;19:49-60.
 48. Pieber TR, Famulla S, Eilbracht J, Cescutti J, Soleymanlou N, Johansen OE, et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). *Diabetes Obes Metab* 2015;17:928-35.
 49. Garg SK, Henry RR, Banks P, Buse JB, Davies MJ, Fulcher GR, et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. *N Engl J Med* 2017;377:2337-48.
 50. Henry RR, Thakkar P, Tong C, Polidori D, Alba M. Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. *Diabetes Care* 2015;38:2258-65.
 51. Rodbard HW, Peters AL, Slee A, Cao A, Traina SB, Alba M. The effect of canagliflozin, a sodium glucose cotransporter 2 inhibitor, on glycemic end points assessed by continuous glucose monitoring and patient-reported outcomes among people with type 1 diabetes. *Diabetes Care* 2017;40:171-80.
 52. Peters AL, Henry RR, Thakkar P, Tong C, Alba M. Diabetic ketoacidosis with canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in patients with type 1 diabetes. *Diabetes Care* 2016;39:532-8.
 53. Kuhadiya ND, Ghanim H, Mehta A, Garg M, Khan S, Hejna J, et al. Dapagliflozin as additional treatment to liraglutide and insulin in patients with type 1 diabetes. *J Clin Endocrinol Metab* 2016;101:3506-15.
 54. Sands AT, Zambrowicz BP, Rosenstock J, Lapuerta P, Bode BW, Garg SK, et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. *Diabetes Care* 2015;38:1181-8.
 55. Shimada A, Hanafusa T, Yasui A, Lee G, Taneda Y, Sarashina A, et al. Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial. *Diabetes Obes Metab* 2018;20:2190-9.
 56. Biester T, Aschemeier B, Fath M, Frey M, Scheerer MF, Kordonouri O, et al. Effects of dapagliflozin on insulin-requirement, glucose excretion and β -hydroxybutyrate levels are not related to baseline HbA1c in youth with type 1 diabetes. *Diabetes Obes Metab* 2017;19:1635-9.
 57. Edelman S, Garg S, Frias J, Maggs D, Wang Y, Zhang B, et al. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. *Diabetes Care* 2006;29:2189-95.
 58. Marrero DG, Crean J, Zhang B, Kellmeyer T, Gloster M, Herrmann K, et al. Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes. *Diabetes Care* 2007;30:210-6.
 59. Kovatchev BP, Crean J, McCall A. Pramlintide reduces the risks associated with glucose variability in type 1 diabetes. *Diabetes Technol Ther* 2008;10:391-6.
 60. Herrmann K, Frias JP, Edelman SV, Lutz K, Shan K, Chen S, et al. Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy. *Postgrad Med* 2013;125:136-44.
 61. Ratner RE, Dickey R, Fineman M, Maggs DG, Shen L, Strobel SA, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial. *Diabet Med* 2004;21:1204-12.
 62. Ratner R, Whitehouse F, Fineman MS, Strobel S, Shen L, Maggs DG, et al. Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets. *Exp Clin Endocrinol Diabetes* 2005;113: 199-204.
 63. Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. *Diabetes Care* 2002; 25:724-30.
 64. Riddle MC, Yuen KC, de Bruin TW, Herrmann K, Xu J, Ohm-

- an P, et al. Fixed ratio dosing of pramlintide with regular insulin before a standard meal in patients with type 1 diabetes. *Diabetes Obes Metab* 2015;17:904-7.
65. Mathieu C, Dandona P, Gillard P, Senior P, Hasslacher C, Araki E, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 Study): 24-week results from a randomized controlled trial. *Diabetes Care* 2018;41:1938-46.
66. Rosenstock J, Marquard J, Laffel LM, Neubacher D, Kaspers S, Cherney DZ, et al. Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials. *Diabetes Care* 2018;41:2560-9.